Prof Robert F Storey discusses the latest findings on dual antiplatelet therapy (DAPT) for the treatment of patients with coronary artery disease (CAD).
Could you summarise the key recent data being reported on DAPT?
Was any of this data surprising and does it need further research?
Do we need to review the role of aspirin in antiplatelet therapy?
Should this data impact practice and potentially guidelines?
What is your preferred strategy for stable patients?
What is your preferred strategy for ACS patients?
Filmed in London at BCIS ACI 2020.
Interviewer: Mirjam Boros
Videographer: Natacha Wienand / Dominic Woodruff